PROCESS FOR THE PREPARATION OF NON-GENOTOXIC DIACETYLRHEIN (DIACEREIN) AND FORMULATIONS COMPRISING NON-GENOTOXIC DIACETYLRHEIN
    1.
    发明申请
    PROCESS FOR THE PREPARATION OF NON-GENOTOXIC DIACETYLRHEIN (DIACEREIN) AND FORMULATIONS COMPRISING NON-GENOTOXIC DIACETYLRHEIN 审中-公开
    制备非基因型二乙酰基甘氨酸(DIACEREIN)的方法和包含非基因型二乙酰基甘氨酸的制剂

    公开(公告)号:WO2010000879A3

    公开(公告)日:2010-04-08

    申请号:PCT/EP2009064555

    申请日:2009-11-03

    摘要: The present invention is directed to a process for producing non-genotoxic Diacetylrhein (Diacerein), comprising: i) transformation of raw Diacerein (or raw Rhein), into a water-soluble salt; ii) adsorption of the salt Diacerein (or Rhein) solution on a hydrophobic resin; iii) washing with an appropriate solvent to eliminate the impurities (in particular the genotoxic impurities); iv) elution to recover Diacereinor Rhein; v) if the process is applied to Rhein, its transformation to Diacerein by acetylation; vi) acidification of purified Diacerein and its recovery, and drying. The invention is also directed to non-genotoxic Diacerein obtained by the process of the invention, in which the total content of genotoxic impurities is below 1ppm, and suitable for the preparation of pharmaceutical formulations, in particular capsules, for human and veterinary use, in agreement with the current Health Authorities request.

    摘要翻译: 本发明涉及生产无基因毒性的二乙酰纤维素(双醋瑞因)的方法,包括:i)将原始双醋瑞因(或生大黄酸)转化为水溶性盐; ii)盐双醋瑞因(或大黄酸)溶液在疏水性树脂上的吸附; iii)用合适的溶剂洗涤以消除杂质(特别是遗传毒性杂质); iv)洗脱以回收Diacereinor Rhein; v)如果该过程应用于Rhein,则其通过乙酰化转化为双醋瑞因; vi)纯化的双醋瑞因的酸化及其回收和干燥。 本发明还涉及通过本发明方法获得的非基因毒性的双醋柳黄素,其中基因毒性杂质的总含量低于1ppm,并且适用于制备用于人和兽医用途的药物制剂,特别是胶囊 与当前的卫生当局请求达成一致。

    PROCEDE DE SYNTHESE DE LA RHEIN ET DE SES DERIVES
    5.
    发明申请
    PROCEDE DE SYNTHESE DE LA RHEIN ET DE SES DERIVES 审中-公开
    合成瑞芬及其衍生物的方法

    公开(公告)号:WO2008090078A1

    公开(公告)日:2008-07-31

    申请号:PCT/EP2008/050500

    申请日:2008-01-17

    摘要: Procédé de synthèse d'un composé de formule (1) dans laquelle R 1 représente un groupement hydroxyle ou acétoxy, caractérisé en ce qu' il comprend : - une étape de métallation du cycle aromatique d'un composé de formule (2) dans laquelle R 2 et R 3 représentent indépendamment un groupement alkyle en C 1 à C 4 , sélectivement en position ortho du substituant -OR 2 ; - la réaction du composé métallé ainsi obtenu avec un composé de formule (3) dans laquelle R 2 est tel que défini ci-dessus, et R 4 est un groupement électrophile pouvant être choisi dans le groupe comprenant les groupements -CHO, -COX avec X=Cl, Br, I, -COCN, -CONCH 3 OCH 3 , -CON(R) 2 , -COOR ou R représente un groupement alkyle en C 1 à C 4 et est de préférence un groupement -CHO ou -COCl; - suivie par des étapes d'hydrolyse acide, de réduction, de cyclisation et d'oxydation conduisant au composé (1).

    摘要翻译: 本发明涉及一种合成式(1)化合物的方法,其中R 1是羟基或乙酰氧基,其特征在于它包括:化合物的芳族化合物的金属化步骤 式(2)的化合物,其中R 2和R 3独立地表示C 1 -C 4亚烷基 在-OR 2取代基的邻位选择性地选择性地; 使由此获得的金属化合物与式(3)化合物反应,其中R 2 2定义如上所定义,R 4是选自以下的亲电子基团:包括 以下基团-CHO,-COX,其中X = Cl,Br,I,-COCN,-CONCH 3,OCH 3,-CON(R) -COOR或R为C 1 -C 4烷基,优选为-CHO或-COCl基; 然后进行酸水解,还原,循环和氧化的步骤,以获得化合物(1)。

    DISALICYLATE ANALOG BASED SIALYL LEWIS<x> MIMETICS
    6.
    发明申请
    DISALICYLATE ANALOG BASED SIALYL LEWIS MIMETICS 审中-公开
    低聚糖唾液酸基路易斯效法类似的基于双水杨酸

    公开(公告)号:WO99029706A2

    公开(公告)日:1999-06-17

    申请号:PCT/US1998/025788

    申请日:1998-12-04

    摘要: The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewis (sLe ), but have a structure capable of mimicking the structural features necessary for selectin recognition. In particular, the invention compounds mimic the key structural features of the oligosaccharides responsible for selectin-mediated cell adhesion. These features consist of the charge-distance-coordination relationship between the carboxylic acid functionality of sialic acid at a distance of 8-12 angstroms of the L-fucose moiety. The invention compounds are disalicylate, its analogs, and disalicylate-based C-glycoside compounds. The present invention also discloses methods of treating selectin-mediated disorders comprising administering the compounds disclosed.

    摘要翻译: 本发明涉及由结构模仿选择素配体,其结合到某些选择素和那些不含唾液酸和/或岩藻糖的天然选择蛋白的配体中,该低聚糖的唾液酸组成的药物 -Lewis x(sLe x),但其具有能够模仿识别选择素所必需的结构特征的结构。 特别地,本发明的化合物具有模拟负责选择素诱导的细胞粘附的寡糖的关键结构特征的性质。 这些特征包括关系唾液酸的羧酸官能团之间的部分L-岩藻糖的8至12埃的距离负载距离协调。 本发明的化合物是二水杨酸酯,其类似物和基于二水杨酸酯的C-糖苷化合物。 本发明还提供了通过施用所呈现的化合物来治疗选择素介导的疾病的方法。

    PROCESS FOR THE PREPARATION OF NON-GENOTOXIC DIACETYLRHEIN (DIACEREIN) AND FORMULATIONS COMPRISING NON-GENOTOXIC DIACETYLRHEIN
    7.
    发明申请
    PROCESS FOR THE PREPARATION OF NON-GENOTOXIC DIACETYLRHEIN (DIACEREIN) AND FORMULATIONS COMPRISING NON-GENOTOXIC DIACETYLRHEIN 审中-公开
    制备非生物碱性二乙酰胆碱(DIACEEIN)的方法和包含非生物碱性二乙酰胆碱的制剂

    公开(公告)号:WO2010000879A2

    公开(公告)日:2010-01-07

    申请号:PCT/EP2009/064555

    申请日:2009-11-03

    摘要: The present invention is directed to a process for producing non-genotoxic Diacetylrhein (Diacerein), comprising: i) transformation of raw Diacerein (or raw Rhein), into a water-soluble salt; ii) adsorption of the salt Diacerein (or Rhein) solution on a hydrophobic resin; iii) washing with an appropriate solvent to eliminate the impurities (in particular the genotoxic impurities); iv) elution to recover Diacereinor Rhein; v) if the process is applied to Rhein, its transformation to Diacerein by acetylation; vi) acidification of purified Diacerein and its recovery, and drying. The invention is also directed to non-genotoxic Diacerein obtained by the process of the invention, in which the total content of genotoxic impurities is below 1ppm, and suitable for the preparation of pharmaceutical formulations, in particular capsules, for human and veterinary use, in agreement with the current Health Authorities request.

    摘要翻译: 本发明涉及一种生产非遗传毒性的二乙酰胆碱(Diacerein)的方法,其包括:i)将生的双醋瑞因(或生的大黄酸​​)转化成水溶性盐; ii)盐将双醋瑞因(或大黄酸)溶液吸附在疏水性树脂上; iii)用适当的溶剂洗涤以除去杂质(特别是基因毒性杂质); iv)洗脱以恢复大鼠精氨酸酯; v)如果该过程适用于莱茵,则其通过乙酰化转化为双醋瑞因; vi)纯化的Diacerein的酸化及其回收,并干燥。 本发明还涉及通过本发明方法获得的非遗传毒性双醋瑞因,其中基因毒性杂质的总含量低于1ppm,并且适用于制备用于人和兽医用途的药物制剂,特别是胶囊 与当前卫生当局的要求达成一致。

    SALTS OF DIHYDROXYANTHRAQUINONE CARBOXYLIC ACIDS AND THEIR THERAPEUTIC USE
    8.
    发明申请
    SALTS OF DIHYDROXYANTHRAQUINONE CARBOXYLIC ACIDS AND THEIR THERAPEUTIC USE 审中-公开
    二羟基四氢喹啉羧酸的盐及其治疗用途

    公开(公告)号:WO2008056156A1

    公开(公告)日:2008-05-15

    申请号:PCT/GB2007/004280

    申请日:2007-11-09

    发明人: WALMSLEY, Andrea

    CPC分类号: C07C66/02

    摘要: A compound of general formula (I): wherein Xi is H or COR 1 and X 2 is H or COR 2 but X 1 and X 2 are not both H; R 1 and R 2 are the same or different and are each C 1-4 alkyl substituted with R 3 , or a four to seven-membered ring which can be optionally substituted with R 8 and can contain one or more additional heteroatoms selected from O, S(O)n and NR 9 ; R 3 is F, CF 3 , OR 4 , NR 5 R 6 or S(O) n R 7 ; R 4 , R 5 and R 6 are the same or different and are each H or C 1-4 alkyl optionally substituted with R 3 , or NR 5 R 6 is a C 4-6 heterocycloalkyl ring containing one or more heteroatoms selected from O, NR 8 and S(O) n ; each n is 0-2; R 7 is C 1-4 alkyl; R 8 is as defined for R 3 or C 1-4 alkyl optionally substituted with R 3 or halogen; R 9 is H or C 1-4 alkyl; Y is NR 9 R 10 R 11 ; and R 10 and R 11 are the same or different and are each H or C 1-6 alkyl optionally substituted with R 3 or halogen, or NR 10 R 11 is a four to seven membered ring which can be optionally substituted with R 8 or COR 1 , and can contain one or more additional heteroatoms selected from O, S(O) n and NR 9 ; and hydrates thereof.

    摘要翻译: 通式(I)的化合物:其中X 1是H或COR 1 X和X 2是H或COR 2,但X 1和X 2不同时为H; R 1和R 2各自相同或不同,并且各自是被R 3 3取代的C 1-4烷基, 或者可以任选地被R 8'取代的4-7元环,并且可以含有一个或多个选自O,S(O)n和NR 9的另外的杂原子; R 3是F,CF 3或OR 4,NR 5 R 6, 或S(O)n R 7 R 7; R 4,R 5和R 6相同或不同,各自为H或C 1-4烷基, 任选被R 3 3或NR 5 R 6取代的烷基是含有一个的C 4-6 - 杂环烷基环 或更多选自O,NR 8和S(O)n的杂原子。 每个n为0-2; R 7是C 1-4烷基; R 8如R 3或C 1-4烷基所定义,任选被R 3或卤素取代; R 9是H或C 1-4烷基; Y为NR 9 R 10 R 11; 且R 10和R 11相同或不同,并且各自为任选被R 3取代的H或C 1-6烷基 或卤素,或NR 10 R 11是可以任选被R 8或COR取代的四元至七元环 并且可以含有一个或多个选自O,S(O)n和NR 9的另外的杂原子。 及其水合物。

    DISALICYLATE ANALOG BASED SIALYL LEWIS<x> MIMETICS
    10.
    发明申请
    DISALICYLATE ANALOG BASED SIALYL LEWIS MIMETICS 审中-公开
    基于模板的SIALYL LEWIS MIMETICS

    公开(公告)号:WO9929706A3

    公开(公告)日:1999-08-12

    申请号:PCT/US9825788

    申请日:1998-12-04

    摘要: The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewis (sLe ), but have a structure capable of mimicking the structural features necessary for selectin recognition. In particular, the invention compounds mimic the key structural features of the oligosaccharides responsible for selectin-mediated cell adhesion. These features consist of the charge-distance-coordination relationship between the carboxylic acid functionality of sialic acid at a distance of 8-12 angstroms of the L-fucose moiety. The invention compounds are disalicylate, its analogs, and disalicylate-based C-glycoside compounds. The present invention also discloses methods of treating selectin-mediated disorders comprising administering the compounds disclosed.

    摘要翻译: 本发明公开了与某些选择蛋白结合的选择蛋白 - 配体结构模拟物的药物,其中模拟物可能缺乏天然选择配体唾液酸路易斯(sLe x)的唾液酸和/或岩藻糖,但具有 能够模拟选择素识别所必需的结构特征的结构。 特别地,本发明化合物模拟负责选择素介导的细胞粘附的寡糖的关键结构特征。 这些特征包括在L-岩藻糖部分的8-12埃的距离处的唾液酸的羧酸官能度之间的电荷 - 距离 - 配位关系。 本发明化合物是二水杨酸酯,其类似物和二水杨酸酯基的C-糖苷化合物。 本发明还公开了治疗选择素介导的病症的方法,包括给予所公开的化合物。